Company news
Genfit SA news in 2025
Genfit SA's news releases, calls and decks from 2025, newest first.
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
December 10, 2025
GENFIT Announces Appointment of new Chief Medical Officer
November 27, 2025
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
November 20, 2025
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
November 20, 2025
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
November 10, 2025
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
November 10, 2025
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
October 30, 2025
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
October 28, 2025
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
September 22, 2025
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
September 19, 2025
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
June 17, 2025
GENFIT Reports First Quarter 2025 Financial Information
May 22, 2025
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
May 20, 2025
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
May 14, 2025
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
May 7, 2025
GENFIT to Present Latest ACLF Research at EASL Congress 2025
May 5, 2025
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
April 29, 2025
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
April 28, 2025